Novo Nordisk stock closes at lowest level since 2021

Cagrisema shows lower weight loss than Eli Lilly's active ingredient tirzepatid in a new study. Novo shares fall to their lowest level in five years.

Sources

Showing 0 of 1 sources

No articles available in your preferred languages.

1 article available in other languages below.

Cagrisema viser et lavere vægttab end Eli Lillys aktive stof tirzepatid i et nyt studie. Novo-aktien falder til laveste niveau i fem år.